Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio Green Med Solution (BGMS) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Bio Green Med Solution (BGMS) over the last 17 years, with Q3 2025 value amounting to $1.1 million.

  • Bio Green Med Solution's Operating Expenses fell 5093.74% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 4071.75%. This contributed to the annual value of $12.0 million for FY2024, which is 5343.79% down from last year.
  • According to the latest figures from Q3 2025, Bio Green Med Solution's Operating Expenses is $1.1 million, which was down 5093.74% from $1.3 million recorded in Q2 2025.
  • Bio Green Med Solution's 5-year Operating Expenses high stood at $8.8 million for Q4 2022, and its period low was $1.1 million during Q3 2025.
  • Moreover, its 5-year median value for Operating Expenses was $5.7 million (2021), whereas its average is $5.0 million.
  • As far as peak fluctuations go, Bio Green Med Solution's Operating Expenses surged by 14676.38% in 2021, and later crashed by 6812.42% in 2024.
  • Quarter analysis of 5 years shows Bio Green Med Solution's Operating Expenses stood at $6.3 million in 2021, then soared by 40.87% to $8.8 million in 2022, then plummeted by 39.05% to $5.4 million in 2023, then plummeted by 66.09% to $1.8 million in 2024, then plummeted by 41.3% to $1.1 million in 2025.
  • Its Operating Expenses stands at $1.1 million for Q3 2025, versus $1.3 million for Q2 2025 and $5.0 million for Q1 2025.